ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, May 4, 2026 at 8:30 a.m. EDT to report first-quarter 2026 financial results and provide operational updates. Participants are asked to register; a North America toll-free dial-in is provided and the webcast will be archived for 30 days.

AI-generated analysis. Not financial advice.

News Market Reaction – ADCT

-4.57%

1 alert

-4.57% News Effect

-$24M Valuation Impact

$501.13M Market Cap

1.43K Volume

On the day this news was published, ADCT declined 4.57%, reflecting a moderate negative market reaction. This price movement removed approximately $24M from the company's valuation, bringing the market cap to $501.13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash balance: $261.3M FY 2025 product revenue: $73.6M FY 2025 net loss: $142.6M +5 more

8 metrics

Cash balance $261.3M Cash and equivalents as of Dec 31, 2025

FY 2025 product revenue $73.6M Full year 2025 product revenue

FY 2025 net loss $142.6M Full year 2025 net loss

Q4 2025 product revenue $22.3M Fourth quarter 2025 product revenue

Warrant shares registered 9,834,776 shares Common shares issuable upon warrant exercise in S-3/424B3

Potential warrant proceeds $37.5 million Maximum cash proceeds if all warrants exercised

Shares outstanding 127,189,572 shares Common shares outstanding as of April 16, 2026 (DEF 14A)

Short interest 4.92% Reported short interest as share of float

Market Reality Check

Price: $3.40 Vol: Volume 930,086 is close t...

normal vol

$3.40 Last Close

Volume Volume 930,086 is close to the 20-day average of 948,277 (relative volume 0.98). normal

Technical Shares at $3.94 are trading above the 200-day MA of $3.76.

Peers on Argus

Momentum scanner shows only INBX with activity, down 3.15% and without news, whi...

1 Down

Momentum scanner shows only INBX with activity, down 3.15% and without news, while sector peers show mixed, mostly modest single-digit moves. This points to stock-specific dynamics rather than a broad biotech move.

Previous Conferences,earnings Reports

5 past events · Latest: Mar 03 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Earnings call scheduling	Neutral	-3.1%	Announced March 10, 2026 call to discuss Q4 and full-year 2025 results.
Nov 03	Earnings call scheduling	Neutral	-6.3%	Set November 10, 2025 call for Q3 2025 results and operational updates.
Nov 03	Earnings call scheduling	Neutral	-6.3%	Repeated announcement for November 10, 2025 Q3 2025 results conference call.
Aug 05	Earnings call scheduling	Neutral	-4.3%	Announced August 12, 2025 call to present Q2 2025 financial results.
May 08	Earnings call scheduling	Neutral	+0.8%	Scheduled May 14, 2025 call for first quarter 2025 results and updates.

Pattern Detected

Prior earnings-call scheduling releases tagged "conferences,earnings" were typically followed by modest single-digit price moves, with an average move of about -3.85% and mostly negative reactions.

Recent Company History

Over the last year, ADC Therapeutics has repeatedly announced quarterly results conference calls, including events on May 14, 2025, August 12, 2025, November 10, 2025, and March 10, 2026. These "conferences,earnings" notices mainly serve to schedule calls and webcasts. Historical 24-hour moves around such announcements clustered in the low single digits, often negative, with an average move of -3.85%. Today’s first-quarter 2026 call notice continues this established communications pattern.

Historical Comparison

-3.9% avg move · In the past year, ADCT issued 5 similar "conferences,earnings" call notices, with an average 24-hour...

conferences,earnings

-3.9%

Average Historical Move conferences,earnings

In the past year, ADCT issued 5 similar "conferences,earnings" call notices, with an average 24-hour move of -3.85%. Today’s Q1 2026 call announcement fits this established pattern of routine scheduling updates.

Consistent quarterly pattern of earnings conference call scheduling across 2025–2026, supporting regular disclosure around financial results and operational updates.

Regulatory & Risk Context

Active S-3 Shelf · $37.5 million

Shelf Active

Active S-3 Shelf Registration 2026-03-10

$37.5 million registered capacity

An effective S-3 resale registration dated March 10, 2026 covers up to 9,834,776 common shares issuable upon exercise of warrants. The company is not selling shares under this prospectus and receives no resale proceeds, but could receive up to $37.5 million in cash if the warrants are fully exercised, earmarked for working capital and general corporate purposes.

Market Pulse Summary

This announcement schedules ADC Therapeutics’ first-quarter 2026 results call for May 4, 2026 at 8:3...

Analysis

This announcement schedules ADC Therapeutics’ first-quarter 2026 results call for May 4, 2026 at 8:30 a.m. EDT, continuing a regular pattern of quarterly "conferences,earnings" updates. Historically, such notices have been followed by modest single-digit moves, with an average reaction of -3.85%. Investors may focus on upcoming financial details following 2025 product revenue of $73.6M and a net loss of $142.6M, as well as any commentary on warrants covering 9,834,776 shares and potential $37.5 million in proceeds.

Key Terms

antibody drug conjugates, adc, webcast, schedule 13g/a, +4 more

8 terms

antibody drug conjugates medical

"a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

adc medical

"pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host"

An antibody-drug conjugate (ADC) is a targeted cancer medicine that pairs an antibody that recognizes specific markers on tumor cells with a potent cell-killing drug, connected so the toxic payload is delivered directly to the cancer. For investors, ADCs matter because successful ADCs can improve patient outcomes and reduce side effects compared with traditional chemotherapy, shaping clinical trial success, regulatory approval chances, commercial demand, and a company’s valuation much like a guided missile versus a general bomb.

webcast technical

"conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

schedule 13g/a regulatory

"[SCHEDULE 13G/A] ADC Therapeutics SA Amended Passive Investment Disclosure"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

def 14a regulatory

"[DEF 14A] ADC Therapeutics SA Definitive Proxy Statement"

A Form 14A is a document that companies send to shareholders before important meetings, such as votes on company decisions. It provides detailed information about the topics to be discussed or voted on, helping shareholders make informed choices. This form is essential because it ensures transparency and allows investors to understand what they are approving or rejecting.

424b3 regulatory

"[424B3] ADC Therapeutics SA Prospectus Filed Pursuant to Rule 424(b)(3)"

A 424B3 is an official SEC prospectus filing that publishes the final terms and details of a securities offering after a company’s registration statement is effective. Investors use it like a product label: it lists what’s being sold, the exact price, how many shares or bonds, and how the deal may dilute existing ownership, so it helps assess immediate financial impact and transparency before deciding to buy or sell.

s-3 regulatory

"[S-3] ADC Therapeutics SA Shelf Registration Statement"

A Form S-3 is a streamlined registration filing that eligible, already-public U.S. companies use to offer new stocks or bonds to investors more quickly and with less paperwork. Think of it as a pre‑approved fast pass that lets a company raise money on shorter notice; for investors it signals the issuer meets certain reporting and size standards and can affect share supply, potential dilution, and market liquidity.

warrants financial

"common shares issuable upon exercise of warrants issued to HCR on February 18, 2026"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA^® (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission, acceptance and outcome of review of the sBLA submission, and full FDA approval; the Company's ability to grow ZYNLONTA^® revenue in the United States and potential peak revenue; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness, the impact on our future revenue streams, and the significant cash required to service such indebtedness; the impact, if any, from the amendment to the agreement with HealthCare Royalty Management and our strategic alternatives; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-host-first-quarter-2026-financial-results-conference-call-on-may-4-2026-302747362.html

SOURCE ADC Therapeutics SA

FAQ

When is the ADC Therapeutics (ADCT) Q1 2026 conference call scheduled?

The ADCT Q1 2026 call is scheduled for May 4, 2026, at 8:30 a.m. EDT. According to the company, the event will report first-quarter 2026 financial results and provide operational updates to investors and analysts.

How can investors access the ADC Therapeutics (ADCT) May 4, 2026 webcast?

Investors can access the live webcast via the ADC Therapeutics investor website at ir.adctherapeutics.com under Events and Presentations. According to the company, registration is available in advance and the webcast page will host the live stream.

Is registration required for the ADC Therapeutics (ADCT) conference call on May 4, 2026?

The company recommends registering in advance to access the conference call and dial‑in numbers. According to the company, participants may pre-register at any time and are advised to join about 10 minutes before the event start time.

What dial‑in number should North American participants use for the ADCT May 4, 2026 call?

North American participants can use the toll‑free number 1-800-836-8184 to join the call. According to the company, this dial‑in is provided for North America and Canada and registration details are available on the investor site.

Will ADC Therapeutics (ADCT) provide an archived recording of the May 4, 2026 webcast?

Yes, ADC Therapeutics will archive the webcast for 30 days following the call. According to the company, the archived recording will be available under Events and Presentations on the investor website for on‑demand viewing.

What topics will ADC Therapeutics (ADCT) cover during the May 4, 2026 earnings call?

The call will report first-quarter 2026 financial results and provide operational updates. According to the company, the presentation is intended to update investors on recent business developments and the company's near‑term operational status.